During the process, both companies will continue to communicate with EMA about its results from its ongoing phase III study. To date, clinical data suggests that BNT162b2 triggers the production of neutralizing antibodies and TH-1 dominant CD4+ and CD8+ T cells that target SARS-CoV-2.

During the EMA's rolling review, data will be reviewed as it becomes available. Then, once the EMA Committee for Medicinal Products for Human Use (CHMP) decides there is sufficient data, the company can submit the complete application. The early review of data can help CHMP come to its decision quicker on whether the investigational medicine or vaccine should be authorized. Once the complete application is submitted, the EMA will determine if the product is granted marketing authorization.

Ideaya, Pfizer expand clinical collaboration
Ideaya Biosciences has expanded its clinical trial collaboration and supply agreement with Pfizer for the combination study of IDE196, a protein kinase...

Javelin, Pfizer to develop organ-on-a-chip platform
Javelin Biotech has entered a three-year collaboration with Pfizer to design and build a platform to evaluate absorption, distribution, metabolism, and...

Pfizer to manufacture Vivet's gene therapy
Vivet Therapeutics and Pfizer have entered into a manufacturing agreement where Pfizer will provide clinical supply for a phase I/II clinical trial evaluating...

Pfizer begins phase I study of COVID-19 drug targeting main protease
Pfizer has begun a phase IB clinical trial to evaluate the safety of an investigational COVID-19 drug candidate, PF-00835321, that blocks the main protease...

Pfizer, BioNTech release preclinical data, talk with EU about COVID-19 vaccine
Preclinical data have demonstrated the ability of BNT162b2, Pfizer and BioNTech's COVID-19 vaccine, to protect against infection. The companies are also...